The side effects of keloid steroid injections nobody warns you about

Steroid injections are the workhorse of keloid treatment, and for good reason. They flatten raised scars, they take the itch away, and they are available almost everywhere. What people are told is that they hurt, that it takes several rounds, and that results vary. What people are usually not told is that the medicine does not stay neatly inside the keloid, and that what it does to the skin around the keloid is a real and reasonably common part of the treatment.

None of this is an argument against having them. It is an argument for knowing what to look for, because most of these effects are dose-related, several are reversible if caught early, and the person best positioned to catch them early is you, four weeks after the shot, in your own bathroom.

The original element in this piece is a monitoring check. Below is a six-point examination to run four weeks after each injection, with what each finding means, whether it typically reverses, and the one sentence that should change the next dose. It exists nowhere else as a single routine, and it is built for the appointment gap, which is where all of these changes actually appear.

Why the side effects happen. The medicine is a corticosteroid, usually triamcinolone, injected directly into the scar tissue. It works by suppressing the overactive fibroblasts and the collagen they keep producing. Corticosteroids do that job wherever they land, and they do not respect the boundary of the keloid. Some of the drug diffuses into the normal skin and fat at the edges, where the same collagen-suppressing action produces thinning rather than flattening. Steroids also affect pigment cells and small blood vessels. So the three classic effects, thinning, lightening, and visible vessels, are the same drug doing the same thing in the wrong place.

This is well described in the literature. Case reporting has documented distinctive patterns of hypopigmentation following intralesional corticosteroid injection, including a stellate or star-shaped pale area spreading outward from the injection site (Am J Case Rep, 2022). Comparative trials of intralesional agents for keloids routinely record these local effects alongside efficacy (J Cosmet Dermatol, 2021).

The four-week check. Do this in good natural light, in a mirror, four weeks after each injection. Photograph the area at the same distance and angle each time. Four weeks is the right interval because it is late enough for these changes to show and early enough to act on before the next dose.

Point one, the height of the keloid. Press gently. Is it flatter and softer than it was before the shot. This is the point of the treatment and it belongs at the top of the list. If nothing has changed after two or three rounds, that is worth raising in its own right, because it may mean the concentration, the technique, or the whole approach needs revisiting.

Point two, the skin at the edge. Look at the normal skin immediately surrounding the scar, not at the scar. You are checking whether it looks thinner, shinier, or slightly sunken compared with the matching area on the other side of your body. Run a fingertip across the border. A soft dip where the skin has become depressed is the sign of atrophy, and it is the most common of these effects.

Point three, color. Look for a pale ring or patch spreading out from where the needle went in. On brown and black skin this is usually the most noticeable effect of all, and it is often what brings people back to the clinic. It can extend well beyond the keloid itself. This is not a burn and it is not permanent damage in most cases, but it can take many months to repigment, which is a long time to look at.

Point four, fine red lines. Small, thread-like red vessels appearing on the surface near the injection site are telangiectasias. They are cosmetic rather than dangerous, and they tend to persist rather than fade on their own.

Point five, the wider area. Check whether any of the above extends noticeably past the edges of the scar. Effects confined to the keloid itself are largely acceptable. Effects spreading a centimetre or more into normal skin are a dose and placement signal.

Point six, symptoms. Note the itch and the pain, both of which usually improve, and note anything new: numbness, tenderness that has increased rather than decreased, or any opening or ulceration in the scar surface. That last one is not part of the expected picture and it needs to be reported rather than monitored.

What reverses and what does not. The honest breakdown. Atrophy, the thinning and denting, usually improves over months once injections stop or the dose comes down, and often resolves fully. Hypopigmentation, the pale halo, usually repigments, but slowly, commonly over six to eighteen months, and it can be a source of real distress in the meantime, particularly on deeper skin tones where the contrast is high. There is a broader picture of how keloid treatment interacts with skin of color that is worth reading alongside this. Telangiectasias tend to persist and generally need a separate vascular laser treatment if they bother you. Any of the above after many repeated high-dose rounds is less likely to fully reverse, which is the single strongest argument for catching it at round two rather than round six.

The sentence that changes the next dose. Bring your photographs and say this: the scar is responding, and I am also seeing thinning and lightening in the normal skin around it, so I want to talk about concentration and placement before the next round. That framing does the work, because it tells your clinician you want to continue while flagging the specific finding that adjusts how. There are several levers available in response, including lowering the concentration, changing the injection depth, spacing sessions further apart, splitting the dose across more sites, or adding or switching to a different intralesional agent. Which lever is right is a clinical judgment, but none of them get pulled if the observation never arrives.

What the studies do not tell you. Three gaps worth naming. First, most trials report these effects as adverse events counted at the end of a study, so we know they happen and we do not have good data on how often they happen at a given concentration in a given skin tone. Second, and more pointedly, almost none of the published work stratifies hypopigmentation risk by skin tone, despite the fact that keloids disproportionately affect people with deeply pigmented skin and that a pale halo is far more visible on that skin. That is a striking blind spot in a literature about a condition with that epidemiology. Third, there is essentially no research on time to repigmentation, which is the question patients actually ask. The six to eighteen month range that gets quoted is clinical experience, not a measured figure.

The reason to keep going anyway. Read against the alternative, these are manageable trade-offs. Untreated keloids continue to grow, itch, and pull, and excision alone has a high recurrence rate without an adjunct like injections. Steroid injections remain first line because they work. The purpose of this check is to keep the treatment going at a dose that flattens the scar without quietly trading the keloid for a pale, thinned patch of skin the same size.

If you are seeing any of these effects and are not sure whether they warrant a visit before your next scheduled round, they do, and that is what the appointment is for. Setting realistic expectations at the start includes knowing what the treatment costs as well as what it gives you. The American Academy of Dermatology maintains a general overview of keloid treatment options for further reading.